(Q36893605)

16 August 2017

title

Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease (English)

1 reference

16 August 2017

1 reference

Fedorova NV

1

1 reference

16 August 2017

Chigir' IP

series ordinal

2

1 reference

16 August 2017

publication date

1 July 2007

1 reference

Neuroscience and Behavioral Physiology

16 August 2017

published in

1 reference

16 August 2017

volume

37

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

539-546

1 reference

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11055-007-0050-3

Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11055-007-0050-3

The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11055-007-0050-3

Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11055-007-0050-3

Drug treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11055-007-0050-3

Dopamine agonists in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11055-007-0050-3

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.

1 reference

12 December 2020

The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease

1 reference

12 December 2020

Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease

1 reference

12 December 2020

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

12 December 2020

A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group

1 reference

12 December 2020

Dopaminergic agonists in the treatment of Parkinson's disease

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Pramipexole in patients with early Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.

1 reference

12 December 2020

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

1 reference

12 December 2020

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

1 reference

12 December 2020

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

A functional test identifies dopamine agonists selective for D3 versus D2 receptors.

1 reference

12 December 2020

Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells

1 reference

12 December 2020

Pramipexole in Parkinson disease. Results of a treatment observation

1 reference

12 December 2020

A rationale for dopamine agonists as primary therapy for Parkinson's disease

1 reference

12 December 2020

Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients

1 reference

12 December 2020

Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications

1 reference

12 December 2020

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

1 reference

12 December 2020

A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group

1 reference

12 December 2020

Efficacy and tolerability of dopamine agonists in a parkinsonian population

1 reference

12 December 2020

Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study

1 reference

12 December 2020

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

1 reference

12 December 2020

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

12 December 2020

Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease

1 reference

12 December 2020

10.1007/S11055-007-0050-3

Identifiers

DOI

1 reference

16 August 2017

1 reference